ABSTRACT
At the present stage of development there is a chance to anticipate and shape the area of genetic "susceptibility" testing by regulations and clear policies. There is a risk that some employers may perceive genetic testing as a way to reduce their costs by decreasing the number of sick employees or compensation claims. Other regulatory actions are needed with regard to direct-to-consumer advertising, which should be limited and should meet predetermined standards and guidelines. Policy makers should view new and expanded expenditures in the area of genetic testing and therapy with the question of cost in mind, a healthy scepticism, and an evaluation of who is advocating such expenditures and whether they are ones who will gain. There is a serious problem with conflict of interest in all areas of genomic medicine, both genetic testing and gene therapy, as large commercial enterprises are involved that have a vested interest in pushing their own agenda regardless of the greater good.
